3 citations
,
November 2019 in “Journal of dermatology” Itraconazole effectively treated a woman's painful skin condition and hair loss.
May 2024 in “Psychiatric News” Weight-loss drugs are not linked to suicidal thoughts.
October 2024 in “Journal of the Endocrine Society” A single steroid injection can cause serious side effects like Cushing Syndrome.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” Setipiprant did not significantly improve hair growth in men with hair loss.
4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
14 citations
,
January 2018 in “Endocrine” Cantú syndrome may be linked to pituitary adenomas.
Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
7 citations
,
June 2010 in “Journal of The American Academy of Dermatology” Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
January 2025 in “JCEM Case Reports” Ketoconazole improved symptoms of ACTH-independent Cushing syndrome despite inconclusive initial scans.
April 2025 in “JAAD Case Reports” Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
28 citations
,
January 1985 in “Journal of the American Academy of Dermatology” A girl with citrullinemia developed pili torti, suggesting a link between the hair condition and the metabolic disorder.
14 citations
,
April 2022 in “Molecules” Pulmonary delivery of cepharanthine significantly improves its effectiveness and shows promise for treating lung fibrosis linked to COVID-19.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
15 citations
,
July 2022 in “Frontiers in Pharmacology” Cepharanthine may help treat COVID-19 by targeting similar pathways as other inflammatory diseases.
6 citations
,
September 2024 in “BMC Pulmonary Medicine” Cepharanthine may help treat lung fibrosis by affecting certain immune cells.
October 2023 in “Journal of cystic fibrosis” 39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
6 citations
,
May 2023 in “Molecules” Cepharanthine dry powder inhalers may effectively treat acute lung injury by reducing inflammation.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
October 2008 in “Clin-alert” Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
4 citations
,
September 2024 in “BMC Cancer” Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
4 citations
,
March 2025 in “Journal of Cosmetic Dermatology” Semaglutide may cause hair loss, but more research is needed to confirm this.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.